Bruker Co. (NASDAQ:BRKR) Holdings Decreased by LMR Partners LLP

LMR Partners LLP decreased its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 0.9% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 36,135 shares of the medical research company’s stock after selling 321 shares during the quarter. LMR Partners LLP’s holdings in Bruker were worth $2,495,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Covestor Ltd boosted its stake in shares of Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after acquiring an additional 210 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after buying an additional 218 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after buying an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd acquired a new position in shares of Bruker in the 2nd quarter worth approximately $52,000. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Bruker by 40.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company’s stock worth $81,000 after buying an additional 248 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. TD Cowen dropped their target price on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. Wells Fargo & Company dropped their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Citigroup decreased their price target on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, Barclays decreased their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $79.36.

Bruker Stock Down 3.7 %

NASDAQ BRKR opened at $49.41 on Tuesday. The stock has a fifty day moving average of $62.32 and a 200-day moving average of $65.07. The stock has a market capitalization of $7.49 billion, a P/E ratio of 23.75, a price-to-earnings-growth ratio of 2.46 and a beta of 1.20. Bruker Co. has a 52 week low of $48.85 and a 52 week high of $94.86. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The firm’s quarterly revenue was up 16.4% on a year-over-year basis. During the same period last year, the business posted $0.74 earnings per share. On average, equities research analysts forecast that Bruker Co. will post 2.4 EPS for the current year.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.